NASDAQ
Inozyme Pharma, Inc. (INZY) has a free cash flow growth of -51.78% as of Friday, May 29, 2026. This represents a 1886.96% decrease compared to its 12-month average of -2.61%. Free cash flow growth tracks the year-over-year percentage change in cash generated after capital expenditures.
No price data available for this timeframe.